Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme.

Trial Profile

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
    • 19 Jun 2017 Long-term survival data from this trial published in a VBL Therapeutics Media Release.
    • 06 Jun 2017 Results (n=46) assessing tumour growth of individual patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top